Carl Zeiss Vision International GmbH announces agreement to acquire Brighten Optix

Aalen, Germany | 4 June 2025 | ZEISS Vision Care

This acquisition will enhance the company’s portfolio of myopia management solutions and further reinforce its leading global position in vision care by also integrating specialty contact lenses.

Carl Zeiss Vision International GmbH announced today that it has entered a definitive agreement to acquire 100% of the shares in Brighten Optix, listed on Taipei Exchange. Brighten Optix is a leading player in the field of orthokeratology (short: ortho-k)* and specialty contact lenses. The capability and products of Brighten Optix will now play an important role in ZEISS Vision Care’s long-term strategy and success. With this acquisition, ZEISS Vision Care is making a strong addition to its already successful myopia management portfolio.

Brighten Optix products are already widely available and successfully used by eye care professionals and eye clinics in Greater China and across Southeast Asia. Their proven and innovative portfolio of specialty contact lenses will complement ZEISS Vision Care’s existing myopia control offerings. Ortho-k lenses are used to manage progressive myopia in children; a condition which can lead to high myopia and even loss of sight. Brighten Optix offers some of the market’s most advanced products and brands such as myOK.

“Progressive myopia is one of the biggest vision care challenges we see in the world today. The topic is so important as the sight of children is at risk. We are already proud of our spectacle lens portfolio, which is clinically proven to significantly slow the progression of myopia. But at the same time, we also know that we need to offer even more options to our partners, the doctors and eye care professionals. That is why we are delighted to have found such a great partner. Our future partnership will allow us to meet exactly this need. We will broaden our portfolio and enable our customers to protect and improve the vision of many more children”, says Sven Hermann, CEO of ZEISS Vision Care and Member of the Executive Board of ZEISS. “Furthermore, Brighten Optix is known for its commitment to research and development. With ZEISS’ heritage of leading innovation, I am confident that this common strength will be of even greater advantage in our joint future”, Hermann concludes.

“We are excited to join a leading, worldwide and visionary company like ZEISS,” says Richard Wu, General Manager of Brighten Optix. “Our business has flourished thanks to pioneering, industry-leading products, and we're eager to capitalize on this chance to help grow and shape the future of vision care and in particular contact lenses and myopia management. Personally, I am proud and thankful to everyone at Brighten Optix for their unwavering commitment and expertise in improving and protecting vision over the last 50 years since my father founded the company. And I am confident that the talented teams of Brighten Optix and ZEISS Vision Care will accomplish great things together”, Wu adds.

The acquisition is expected to close early 2026. The transaction remains subject to completion of certain conditions and all applicable regulatory approvals. Morgan Stanley served as exclusive financial advisor to ZEISS Vision Care in relation to this transaction.

^{*Orthokeratology in short Ortho-K: The patient wears form-stable contact lenses at night to change the curvature of the cornea, so the wearer can see well without glasses during the day. These lenses have been shown to reduce the progression of myopia.}